Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
Recruiting · NCT03781752 · Interventional (participants receive a specific treatment) · Lead sponsor: Icahn School of Medicine at Mount Sinai
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
The study team will determine the association between d,l-methylphenidate (MPH) therapeutic outcomes in ADHD patients and genetic variants of CES1 and reveal key associations between CES1 genotypes and the PK and PD of MPH.
Who can take part
Age range
6 Years to 17 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- \- Youth ages 6-17 years with ADHD as a primary diagnosis
Exclusion criteria
- Participants that do not have ADHD as a primary diagnosis
- Participants that do not want, require, or are not healthy enough for a single dose trial of MPH for ADHD per the clinical judgment of the treating and study clinicians
- Participants that are smokers or, are pregnant
Where it is running
4 locations listed across 4 US states.
- University of Florida - Gainesville, Florida, United States
- Icahn School of Medicine at Mount Sinai - New York, New York, United States
- Cincinnati Children's Hospital Medical Center - Cincinnati, Ohio, United States
- Seattle Children's Hospital - Seattle, Washington, United States